converting concept into product

Discovering opportunities, accelerating development and partnering wisely

About Us

Greenfire Bio (GFB)

GFB is an oncology focused clinical stage biopharma company that looks to collaborate with, in-license or acquire early-stage assets and develop them through clinical proof-of-concept and beyond. As we access new assets, we set up new subsidiaries to provide the focus required to advance these into and through the clinic.

How we build success

Medical innovations are precious and exciting and come from all over. Making a good idea in medicine into a product is a difficult and expensive process. It requires expertise and capital often not available for startups completing laboratory proof-of-concept.

That’s where Greenfire comes in. We have assembled highly experienced team of pharmaceutical experts bolstered by a network of advisors and service providers to deploy on late pre-clinical and early clinical assets to accelerate their development into products.

Our extensive network seeks out exciting innovations, engages flexibly with innovators, and accelerates the transition to medical products. We take the unappreciated risks out of development – timely access to expertise and capital. If you think you have an innovation that fits our profile, contact us.

status

Since the inception of the company in 2020, the company has acquired a first-in-class small molecule SIK2/3 inhibitor (GRN300) currently in a Ph1 trial, invested in a company called Pacylex that has a first-in-class NMT1/NMT2 inhibitor (PCLX001) in Ph1 testing for hematological malignancies and in-licensed a novel therapeutic vaccine platform (M-001-004) for solid tumors from the Mayo Clinic that has undergone Ph1 testing. GFB has set up operating subsidiaries for the SIK2/3 inhibitor (Green3Bio) and the therapeutic vaccine products (MGFB Bio).

Opportunity Access

Capitalize on access to innovative preclinical and early-stage clinical products and technology

Development Acceleration

Leverage an integrated ecosystem of development organizations and internal expertise to accelerate product development timelines

Business MONETIZATION

Monetize investments through strategic and well-timed out-licensing, sale or IPO of each product to provide liquidity to investors and the best path to bringing products to patients

Our process sounds simple but execution is where we excel

Acquire pipeline of differentiated products to meet underserved medical needs. If you think you have an innovation that fits our profile, contact us.

Deploy very experienced biopharma team for efficient drug development and business management

Utilize a successful organizational model; leverage virtual operations focused program management and partner ecosystem of service providers

Exit programs after advancing candidates to an appropriate value inflection point

Provide excellent returns to investors by delivering superior products to patients

MANAGEMENT TEAM

Ajit Gill

CEO and Founder, Director

CEO & President Nektar Therapeutics
VP and Gen Mgr Kodak’s Interactive Systems
VP Finance at TRW-Fujitsu

Sanjeev Munshi, PHD, MBA

CBO

SVP, BD & Alliance Management, InveniAI
Ex. Director Merck BD and Discovery

Shailaja Gupta, PhD

Executive Director, CMC

Vikas Agarwal, PhD

VP Program Management

Gayathri Swaminath, PHD, MBA

VP Research

J. Andrew Sanford, MBA

Chief Financial Officer

Markus Peter

VP, Program Lead, GRN-300

Chris Searcy, Chief Corporate Development Officer

CBO Nocion
CBO Respira
CBO Taris
VP Valeritas, Nektar, Pfizer

BOARD OF DIRECTORS

Purnanand Sarma, PhD

CEO Immunome
CEO Taris
GM Cephalon
VP Nektar

Ajit Gill

Director

Chris Searcy, Chief Corporate Development Officer

CBO Nocion
CBO Respira
CBO Taris
VP Valeritas, Nektar, Pfizer